To include your compound in the COVID-19 Resource Center, submit it here.

InterMune Phase III Actimmune IPF data

ITMN said in a double-blind Phase III trial in 330 patients with idiopathic pulmonary fibrosis (IPF), its Actimmune interferon gamma-1b gave about a 10% relative reduction

Read the full 262 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE